Effect of Hormonal Contraception on Lower Urinary Tract Symptoms& Sexual Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

177 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-15

Study Completion Date

2021-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effect of hormonal contraception on lower urinary tract symptoms\& sexual function

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Awareness & Use of Emergency Contraception

NCT04172584

Emergency Contraception

UNKNOWN

Effect of Levonorgestrel Intrauterine System on Hemoglobin Level

NCT06935968

Hemoglobin; Deficiency

NOT_YET_RECRUITING NA

Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity

NCT01953211

Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy

COMPLETED

Quality of Life During Different Regimens of Combined Hormonal Contraceptives in Women of Reproductive Age

NCT06918873

Hormonal Contraception

RECRUITING

Improving Adolescent Adherence to Hormonal Contraception

NCT00584038

Contraception

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is generally accepted that female sex hormones influence the morphology and physiology of vaginal tissues. Peripheral estrogen affects urogenital connective tissue composition and structure, vaginal blood flow, and thickness of vaginal epithelium. Estrogen and progestagen receptors are also abundantly present in the lower urinary tract, which has the same embryonic origin as the vagina. decline in circulating estrogen levels may result in atrophy of vaginal, urethral and bladder trigonal epithelium, as well as initiate metabolic changes in the subepithelial supportive tissues. This process forms the biological rationale for the common clinical practice of prescribing hormone treatment to menopausal women with lower urinary and genital tract symptoms.

Contrary to widespread belief, the Womens Health Initiative (WHI) randomised trial showed that menopausal hormone therapy with conjugated estrogen alone, or in combination with progestagen, increased the risk of de novo or aggravated urinary incontinence after one year of treatment. In premenopausal women, oral contraception is the most common source of hormone intake but very few studies have endeavored to determine the effects of oral contraception on premenopausal urinary incontinence. The aim of this nationwide cohort study was to assess the influence of contraceptives on the risk for lower urinary tract dysfunction in young female.at is time-related with the beginning of hormonal contraception, health care providers should give information about other methods and try to switch them to a method less associated with sexual dysfunction. However, there are contradictory results between the different studies regarding the association between sexual dysfunction and hormonal contraceptives, so it could be firmly said that additional research is needed.

Meanwhile, it could be said that hormonal contraception has been associated with different alterations in sexual functioning.

To conclude, a multidisciplinary approach to the management of female sexual dysfunction is mandatory, and health care providers should give lifestyle counselling apart from proposing different treatment options. An adequate relationship with the patient, as well as the routine monitoring of possible sexual dysfunction, are essential in addressing these difficulties. Undoubtedly, the best contraceptive is one that fulfills the women's needs with acceptable side effects and agreed with the prescribed

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contraception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women taking hormonal contraception e.g cocs .pops.implanon\&.injectable contraception
2. Women has good regular marital life

Exclusion Criteria

1. female has organic urinary dysfunction
2. female has mental\& psycological dysfunction
3. chronic disease DM.hypertension. chronic renal disease
4. prolapse
5. previous perineal \&vaginal correlation surgery
6. women taking any treatment for urinary tract infection \&sexual dysfunction

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No